ASCO GU Symposium 2021

ASCO GU Symposium 2021

Enfortumab Vedotin as Third-Line Treatment Improves Overall Survival for Patients with Advanced Urothelial Carcinoma in the EV-301 Trial

Enfortumab Vedotin as Third-Line Treatment Improves Overall Survival for Patients with Advanced Urothelial Carcinoma...

March 26, 2021

Efortumab vedotin prolonged OS in patients who had previously received chemotherapy and checkpoint inhibitors for advanced urothelial carcinoma.

Lenvatinib plus Pembrolizumab Improves Overall Survival Compared to Sunitinib as First-Line Treatment for Advanced RCC in the CLEAR Trial

Lenvatinib plus Pembrolizumab Improves Overall Survival Compared to Sunitinib as First-Line Treatment for Advanced...

March 26, 2021

Long-Acting Weekly Versus Daily Growth Hormone Therapy For Adult Patients

Adjuvant Nivolumab Improves Disease-Free Survival for Patients with Muscle-Invasive Urothelial Carcinoma in CheckMate 274

March 26, 2021

Cabozantinib Improves Progression-Free Survival over Sunitinib for Metastatic Papillary RCC in SWOG 1500

Cabozantinib Improves Progression-Free Survival over Sunitinib for Metastatic Papillary RCC in SWOG 1500

March 26, 2021

Predicting Early Metastasis in Young Men with Prostate Cancer, Cabazitaxel, Circulating Tumor Cells Are Associated with Survival and Prognosis for Men Receiving Third-line Treatment for Metastatic Castration-resistant Prostate Cancer

Circulating Tumor Cells Are Associated with Survival and Prognosis for Men Receiving Third-line Treatment...

February 22, 2021

177Lu-PSMA-617 Improves Progression-free Survival and Patient-reported Outcomes Compared to Cabazitaxel for Men with Metastatic Castration-resistant Prostate Cancer

177Lu-PSMA-617 Improves Progression-free Survival and Patient-reported Outcomes Compared to Cabazitaxel for Men with Metastatic...

February 22, 2021

Relugolix Effectively Suppresses Testosterone Levels Regardless of Other Simultaneous Prostate Cancer Treatments

Relugolix Effectively Suppresses Testosterone Levels Regardless of Other Simultaneous Prostate Cancer Treatments

February 22, 2021

Enzalutamide Provides Similar Clinical Benefit for Men with Metastatic Hormone-sensitive Prostate Cancer Due to...

February 22, 2021

Curated Journal reading List

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice

June 3, 2022

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice

June 3, 2022

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice

June 3, 2022

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice

June 3, 2022

Adversarial training for prostate cancer classification using magnetic resonance imaging

June 3, 2022

Adversarial training for prostate cancer classification using magnetic resonance imaging

June 3, 2022

Adversarial training for prostate cancer classification using magnetic resonance imaging

June 3, 2022

Adversarial training for prostate cancer classification using magnetic resonance imaging

June 3, 2022

Cancer in the Faroe Islands from 1960-2019 – incidence, mortality, and comparisons with the...

June 3, 2022

Cancer in the Faroe Islands from 1960-2019 – incidence, mortality, and comparisons with the...

June 3, 2022

Advertisement

Expert Interviews

How Racial Disparity and COVID-19 Affect Prostate Cancer Research, with Scott...

December 1, 2020

Oliver Sartor, MD, on Active Surveillance for Prostate Cancer in African...

November 24, 2020